Literature DB >> 34450188

Adherence with protocol medication use and mortality from unrelated causes in a prevention trial.

Paul Pinsky1, Phyllis Goodman2, Howard Parnes3, Leslie Ford3, Lori Minasian3.   

Abstract

Several studies have shown that non-adherence to medication use is associated with lower use of preventive services and increased mortality. We aimed to study the relationship between initial adherence to medication use and mortality in the Prostate Cancer Prevention Trial (PCPT). The PCPT randomized men age 55 and over to a finasteride or placebo arm. Duration of treatment was seven years, followed by end-of-study prostate biopsy. Extended follow-up for mortality was performed by linkage to the National Death Index. Non-adherence was defined as taking under 80% of required pills during the first or second 6-month trial period. Proportional hazards models were used to assess the relationship between adherence and all-cause mortality (excluding prostate cancer deaths). Three models were developed as follows: Model I (controlling for demographics and trial arm), Model II (Model I factors plus specific medical conditions), Model III (Model II factors plus lifestyle factors). Of 18,667 men included in the analysis, 3082 (16.5%) were non-adherent. The most common reasons for non-adherence were side effects (33.9%) and forgetting to take pills (22%). Through 5 and 10 years of follow-up, 178 (5.9%) and 483 (15.7%) non-adherent men died versus 581 (3.7%) and 1887 (12.1%) adherent men. Hazard ratios (HRs) at 5 years were 1.62 (95% CI: 1.37-1.91), 1.55 (95% CI: 1.30-1.83) and 1.49 (95% CI: 1.25-1.76) for Models I-III. HRs at ten years were lower but still statistically significant. Non-adherence to taking protocol medications was associated with increased mortality from unrelated conditions.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Medication; Mortality; Non-adherence; Prevention

Mesh:

Year:  2021        PMID: 34450188      PMCID: PMC9045137          DOI: 10.1016/j.ypmed.2021.106778

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.637


  13 in total

1.  The healthy adherer and the placebo effect.

Authors:  Betty Chewning
Journal:  BMJ       Date:  2006-07-01

2.  The prostate cancer prevention trial: design, biases and interpretation of study results.

Authors:  Phyllis J Goodman; Ian M Thompson; Catherine M Tangen; John J Crowley; Leslie G Ford; Charles A Coltman
Journal:  J Urol       Date:  2006-06       Impact factor: 7.450

3.  Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217).

Authors:  Ellen R Gritz; Kathryn B Arnold; Carol M Moinpour; Allison M Burton-Chase; Catherine M Tangen; Jeffrey F Probstfield; William A See; Michael M Lieber; Vincent Caggiano; Sarah Moody-Thomas; Connie Szczepanek; Anne Ryan; Susie Carlin; Shannon Hill; Phyllis J Goodman; Rose Mary Padberg; Lori M Minasian; Frank L Meyskens; Ian M Thompson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-07-15       Impact factor: 4.254

4.  The association between statin use and outcomes potentially attributable to an unhealthy lifestyle in older adults.

Authors:  Amanda R Patrick; William H Shrank; Robert J Glynn; Daniel H Solomon; Colin R Dormuth; Jerry Avorn; Suzanne M Cadarette; Helen Mogun; M Alan Brookhart
Journal:  Value Health       Date:  2011-04-22       Impact factor: 5.725

5.  Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial.

Authors:  J Irvine; B Baker; J Smith; S Jandciu; M Paquette; J Cairns; S Connolly; R Roberts; M Gent; P Dorian
Journal:  Psychosom Med       Date:  1999 Jul-Aug       Impact factor: 4.312

6.  Statin adherence and risk of all-cause, cancer, and cardiovascular mortality among dyslipidemia patients: A time-dependent analysis.

Authors:  Young Ran Lee; Sarah Soyeon Oh; Sung-In Jang; Eun-Cheol Park
Journal:  Nutr Metab Cardiovasc Dis       Date:  2020-07-25       Impact factor: 4.222

7.  The influence of finasteride on the development of prostate cancer.

Authors:  Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2003-06-24       Impact factor: 91.245

8.  Association of Nonadherence to Cancer Screening Examinations With Mortality From Unrelated Causes: A Secondary Analysis of the PLCO Cancer Screening Trial.

Authors:  Dudith Pierre-Victor; Paul F Pinsky
Journal:  JAMA Intern Med       Date:  2019-02-01       Impact factor: 21.873

9.  Effect of medication adherence on long-term all-cause-mortality and hospitalization for cardiovascular disease in 65,067 newly diagnosed type 2 diabetes patients.

Authors:  Yeon-Yong Kim; Jin-Seok Lee; Hee-Jin Kang; Sang Min Park
Journal:  Sci Rep       Date:  2018-08-15       Impact factor: 4.379

10.  It's Not Too Late to Improve Statin Adherence: Association Between Changes in Statin Adherence from Before to After Acute Myocardial Infarction and All-Cause Mortality.

Authors:  Ryan P Hickson; Jennifer G Robinson; Izabela E Annis; Ley A Killeya-Jones; Gang Fang
Journal:  J Am Heart Assoc       Date:  2019-04-02       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.